KRAS and non-small cell lung carcinoma: One example for such a hypothesis (H1) was: “In patients with KRAS-mutated NSCLC treated with an immune checkpoint inhibitor-containing regimen, the presence of a concurrent serine/threonine kinase 11 loss-of-function mutation is associated with a significantly increased risk of developing severe (Grade 3) immune-mediated colitis.”